에 대한 최신 뉴스 Vista Energy (NYSE:VIST) 주식

Vista Energy

Vista Energy SAB de CV is an independent oil and gas company. It is focused on shale oil and shale gas exploration at its main assets in Vaca Muerta. The company has operations in Argentina and Mexico. The company operates in a single segment- the exploration and production of Crude oil, Natural gas, and LPG. Geographically, It operates in Argentina and Mexico. it generates the majority of its revenue from Argentina.

Las,Vegas,,Usa,-,April,13,,2014:,Hertz,Car,Rental

Equities

Mid Cap

News

Movers

BULL

CERT

MTSR

SBSW

VIST

ZLAB

허츠, 비스타 에너지 등 지난주 급등한 중형주 6종목 (4월 14~18일)

Vista Energy S.A.B. de C.V. American Depositary Shares, each representing one series A share, with no par value

Vista Energy SAB de CV

VISTA OUTDOOR INC COM

VISTA OIL & GAS SAB DE CV by Vista Energy S.A.B. de C.V.

Vista Gold Corp

VISTA GROUP INTL by Vista Group International Ltd.

Vista Group International Ltd

Vistagen Therapeutics, Inc. - Common Stock

Vistagen Therapeutics Inc

Visteon Corp

Vistra Corp

Vistry Group PLC

VISTRY GROUP PLC UNSP/ADR by VISTRY GROUP PLC.

Oppenheimer analyst Michael Wiederhorn maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Outperform and lowers the price target from $600 to $400.

Price Target

Analyst Ratings

Oppenheimer Maintains Outperform on UnitedHealth Group, Lowers Price Target to $400

WIIM

ALLO

Allogene Therapeutics shares are trading lower after the company reported Q1 financial results. Also, Baird and Oppenheimer lowered their respective price targets on the stock.

Cruise line stocks are historically among the strongest seasonal performers in the S&amp;P 500 heading into the second half of May, with Royal Caribbean Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RCL#NYSE">RCL</a>), Norwegian Cruise Line Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NCLH#NYSE">NCLH</a>) and Carnival Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CCL#NYSE">CCL</a>) averaging double-digit returns over a <a href="https://www.benzinga.com/topic/seasonality">three-week window.</a>
Historical data from Seasonax platforms shows that from May 14 to early June, these three stocks have consistently outperformed over the past decade, with average gains north of 10%. 
Among all S&amp;P 500 constituents, they rank at the very top for late-spring seasonality. Seasonal strength is typically fueled by ramping summer demand, strong forward bookings, and an uptick in consumer travel spending ahead of peak vacation months.
Here are the top five S&amp;P 500 stocks by average return in a three-week period starting from May 14:
<figure class="wp-block-table is-style-stripes"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Stock</th>
<th>Avg. Return (Last 10 years)</th>
<th>Max Profit</th>
<th>Max Loss</th>
<th>Win Rate</th>
<th>Pattern Dates</th>
</tr>
</thead>
<tbody>
<tr>
<td>Norwegian Cruise Line</td>
<td>+13.75%</td>
<td>+149.63%</td>
<td>-6.59%</td>
<td>5/10</td>
<td>May 14 – Jun 7</td>
</tr>
<tr>
<td>Caesars Entertainment Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CZR#NASDAQ">CZR</a>)</td>
<td>+11.98%</td>
<td>+102.49%</td>
<td>-0.11%</td>
<td>9/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Royal Caribbean</td>
<td>+11.52%</td>
<td>+113.71%</td>
<td>-7.48%</td>
<td>6/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Carnival Corp.</td>
<td>+11.28%</td>
<td>+103.02%</td>
<td>-5.19%</td>
<td>5/10</td>
<td>May 14 – Jun 6</td>
</tr>
<tr>
<td>Boeing Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BA#NYSE">BA</a>)</td>
<td>+10.69%</td>
<td>+88.13%</td>
<td>-4.95%</td>
<td>8/10</td>
<td>May 14 – Jun 7</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Source: Seasonax</figcaption></figure>
<h3 class="wp-block-heading">RCL Sees Strong Summer Bookings</h3>
In a note from late April, Goldman Sachs analyst Lizzie Dove pointed to a strong reversal in booking momentum despite broader macro uncertainty and uneven travel data across the sector.
April bookings at RCL exceeded the same month last year, while close-in bookings remained firm. 
The company also reported stronger-than-usual onboard spending and pre-cruise purchases. Forward bookings for 2026 were tracking in line with 2024 levels but at higher prices—a sign of pricing power in an inflation-sensitive market.
With approximately 86% of the 2025 cruise calendar already booked, Dove's team raised their estimates and lifted the stock's price target from $245 to $260. However, they retained a slightly more cautious tone in 2026, pending more clarity on consumer resilience.
Since hitting tariff-driven lows on April 9, shares of RCL have surged 50% through mid-May —more than twice the gain of the S&amp;P 500. CCL shares matched the performance during the same period. 
<h3 class="wp-block-heading">NCLH Flags Demand Softness Amid Macro Pressures</h3>
In contrast, Norwegian Cruise Line is facing a different set of conditions. 
In early May, Bank of America analyst Andrew Didora highlighted NCLH as the first in the group to show softness in its 12-month forward-booked position.
While this wasn't viewed as unexpected—given the macro backdrop, consumer sentiment, and fare discounts introduced under the Oceania brand—it raised questions about forward pricing discipline across the cruise industry. Didora added that weakening demand isn't isolated to NCLH, and other operators may be seeing similar dynamics. 
BofA cut its 2025 and 2026 EPS forecasts for NCLH by 3% and 2%, now expecting $2.07 and $2.53, respectively. It revised the price objective down from $23 to $20 while maintaining a Neutral rating on concerns around leverage and top-line pressures.
Shares of NCLH have rallied 36% since April lows, underperforming versus peers. 
Read now: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/government/regulations/25/05/45298562/chipmakers-enter-bullish-seasonal-window-5-stocks-that-could-outperform">Chipmakers Enter Bullish Seasonal Window: 5 Stocks That Could Outperform </a></li>
</ul>
Photo: Shutterstock

Travel

ENPH

NCLH

Cruises Set Sail Ahead Of Summer Boom: These 3 S&P 500 Stocks Show Strongest Late-May Seasonality

Oppenheimer analyst Jay Olson maintains Inovio Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INO#NASDAQ">INO</a>) with a Outperform and lowers the price target from $15 to $13.

Oppenheimer Maintains Outperform on Inovio Pharmaceuticals, Lowers Price Target to $13

Wells Fargo analyst Yanan Zhu maintains Adaptimmune Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ADAP#NASDAQ">ADAP</a>) with a Equal-Weight and lowers the price target from $1.5 to $1.

ADAP

Wells Fargo Maintains Equal-Weight on Adaptimmune Therapeutics, Lowers Price Target to $1

Wells Fargo analyst Eva Fortea Verdejo maintains ITeos Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ITOS#NASDAQ">ITOS</a>) with a Overweight and lowers the price target from $16 to $13.

ITOS

Wells Fargo Maintains Overweight on ITeos Therapeutics, Lowers Price Target to $13

CREX

Creative Realities shares are trading higher. The company reported Q1 financial results.

Oppenheimer analyst Timothy Horan initiates coverage on Core Scientific (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CORZ#NASDAQ">CORZ</a>) with a Outperform rating and announces Price Target of $15.

Initiation

Core Scientific, Inc. - Class A Common Stock

CORZ

Oppenheimer Initiates Coverage On Core Scientific with Outperform Rating, Announces Price Target of $15

Wells Fargo analyst Larry Biegelsen maintains Hyperfine (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HYPR#NASDAQ">HYPR</a>) with a Equal-Weight and lowers the price target from $1.29 to $0.68.

HYPR

Wells Fargo Maintains Equal-Weight on Hyperfine, Lowers Price Target to $0.68

The Tampa Bay Lightning have entered into a multi-year media rights agreement with Scripps Sports, which will make it easier than ever for fans throughout the Tampa Bay area to watch Lightning hockey games for free beginning with the start of the 2025-26 NHL season this fall.
This new agreement allows The E.W. Scripps Company (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSP#NASDAQ">SSP</a>) to produce and distribute all preseason, regular season and first-round playoff Lightning games that are not allocated exclusively to national broadcasts.
 &nbsp;

Tampa Bay Lightning Enters Into Multi-year Media Rights Agreement With Scripps Sports

BDSX

Biodesix shares are trading lower after the company reported worse-than-expected Q1 financial results and cut its FY25 sales guidance below estimates.

By Javier Hasse via <a href="https://elplanteo.com/industria-cannabis-uruguay-2025/">El Planteo</a>
As debates over <a href="https://www.benzinga.com/cannabis">cannabis</a> reform continue across the globe, one country has a full decade of experience to draw from—and it just lost the man who helped make it happen.
This week, <a href="https://elplanteo.com/pepe-mujica-diario-che-guevara/">José "Pepe" Mujica</a>, the former Uruguayan president who oversaw the world's first full legalization of adult-use cannabis, <a href="https://www.benzinga.com/markets/cannabis/25/05/45392507/first-president-to-legalize-cannabis-has-died-honoring-uruguays-pepe-mujicas-legacy">passed away at the age of 89</a>. Widely revered for his humility, progressive ideals and radical honesty, Mujica's cannabis law was never about business; it was about dismantling hypocrisy and improving public health.
A decade later, the legacy of that 2013 law was front and center at C-Days 2025, a global cannabis and psychedelics summit held in Barcelona. Speaking at the event, <a href="https://elplanteo.com/industria-cannabis-uruguay-2025/">Mercedes Ponce de León</a>, founder of Latinnabis and director of Expo Cannabis Uruguay, offered a data-rich overview of Uruguay's cannabis model: its results, its limits and what it can teach the rest of the world.
<h3 class="wp-block-heading">Three Legal Channels, Over 100,000 Registered Consumers</h3>
Uruguay's adult-use system offers three legal pathways for non-medical cannabis access:
<ul class="wp-block-list">
<li>Home grow: Up to 6 flowering female plants and 480 grams per year.</li>
<li>Cannabis clubs: Non-profit associations of 15 to 45 members, with up to 99 plants and a 40-gram monthly cap per person.</li>
<li>Pharmacies: Up to 10 grams per week, sold in 5-gram packs, with four THC-limited strains authorized (up to 20% THC).</li>
</ul>
As of early 2025, 102,125 users were officially registered across these access points:
<ul class="wp-block-list">
<li>11,465 home growers</li>
<li>15,162 cannabis club members</li>
<li>75,498 pharmacy purchasers</li>
</ul>
There are also more than 460 licensed clubs and 40 pharmacies participating in the program.
<h3 class="wp-block-heading">What's Available In Pharmacies—And At What Cost?</h3>
Uruguay's state-controlled pharmacy model currently offers four cannabis strains, each with a unique THC/CBD profile and pricing structure:
<figure class="wp-block-table"> 
<table class="has-fixed-layout">
<thead>
<tr>
<th>Strain</th>
<th>%THC</th>
<th>%CBD</th>
<th>Psychoactivity</th>
<th>Price (UYU)</th>
<th>Approx. USD</th>
</tr>
</thead>
<tbody>
<tr>
<td>Alfa</td>
<td>≤9</td>
<td>≥3</td>
<td>Medium/Low</td>
<td>$470</td>
<td>$11.24</td>
</tr>
<tr>
<td>Beta</td>
<td>≤9</td>
<td>≥3</td>
<td>Medium/Low</td>
<td>$490</td>
<td>$11.71</td>
</tr>
<tr>
<td>Gamma</td>
<td>≤15</td>
<td>≤1</td>
<td>High</td>
<td>$550</td>
<td>$13.15</td>
</tr>
<tr>
<td>Épsilon</td>
<td>≤20</td>
<td>≤1</td>
<td>High</td>
<td>$600</td>
<td>$14.34</td>
</tr>
</tbody>
</table>
</figure>
While pharmacies remain the most used access point, Mercedes Ponce de León noted that restrictions on potency, format and availability continue to limit impact and consumer satisfaction.
<h3 class="wp-block-heading">Is It Working?</h3>
Yes, though not without caveats. According to official data shared during her presentation:
<ul class="wp-block-list">
<li>Problematic cannabis use has remained stable at 2.1% since 2011.</li>
<li>Overall cannabis consumption declined from 14.6% in 2018 to 12.3% in 2024.</li>
<li>Average age of first use rose from 18 to 20 years.</li>
<li>The illicit market has shrunk significantly.</li>
</ul>
Meanwhile, Uruguay's 2024 National Drug Survey showed that 37% of cannabis users now access the plant through legal means.
<h3 class="wp-block-heading">What Still Needs Work?</h3>
Despite strong public health outcomes, the model faces several persistent challenges:
<ul class="wp-block-list">
<li>Lack of product variety and innovation</li>
<li>Uneven geographic access, with few pharmacies outside major cities</li>
<li>Logistical and financial barriers to exports</li>
<li>A broader drug policy framework that remains punitive in other areas</li>
</ul>
Ponce de León outlined four priority actions for 2025 and beyond:
<ol class="wp-block-list">
<li>Foster stronger public-private collaboration</li>
<li>Invest in research and development</li>
<li>Update regulations to expand legal access and improve user experience</li>
<li>Integrate Uruguay into global markets through ethical and sustainable trade</li>
</ol>
<h3 class="wp-block-heading">What&#8217;s Next?</h3>
Uruguay did what many countries are still debating: build a legal cannabis system that reduces harm, shrinks the illicit market and respects consumer rights. The outcomes are measurable. But so are the gaps.
In Ponce de León's words, "The positive impact is proven. But if the framework isn't updated—if access doesn't expand and innovation isn't guaranteed—the model risks becoming symbolic rather than functional."
As the world mourns the passing of Pepe Mujica, Uruguay's cannabis experiment stands as part of his lasting legacy. The road ahead will determine whether that legacy deepens—or stalls.
This article is from an external, unpaid contributor. It does not represent Benzinga's reporting and has not been edited for content or accuracy.
Photo: Shutterstock

Cannabis

Latin America

Legal Cannabis, 10 Years Later: Real Data From The First Country To Do It

Oppenheimer analyst Timothy Horan initiates coverage on Digital Realty Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DLR#NYSE">DLR</a>) with a Outperform rating and announces Price Target of $200.

Oppenheimer Initiates Coverage On Digital Realty Trust with Outperform Rating, Announces Price Target of $200

a.k.a. Brands Holding shares are trading higher after the company reported better-than-expected Q1 financial results and issued FY25 sales guidance below estimates.

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 1.022M Barrel Draw Vs 0.600M Barrel Draw Est.; 0.188M Barrel Build Prior

EIA Weekly Distillates Stocks 3.155M Barrel Draw Vs 0.100M Barrel Build Est.; 1.107M Barrel Draw Prior

Cantor Fitzgerald analyst Jonathan Ruykhaver reiterates SoundThinking (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSTI#NASDAQ">SSTI</a>) with a Overweight and maintains $20 price target.

Reiteration

SSTI

Cantor Fitzgerald Reiterates Overweight on SoundThinking, Maintains $20 Price Target

Macro Notification

General

USA Crude Oil Inventories 3.454M Barrel Build Vs 2.000M Barrel Draw Est.; 2.032M Barrel Draw Prior

Zoetis (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZTS#NYSE">ZTS</a>) has outperformed the market over the past 10 years by 2.07% on an annualized basis producing an average annual return of 12.73%. Currently, Zoetis has a market capitalization of $71.42 billion. 
Buying $100 In ZTS: If an investor had bought $100 of ZTS stock 10 years ago, it would be worth $336.54 today based on a price of $160.43 for ZTS at the time of writing.
<h3>Zoetis's Performance Over Last 10 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1747233012_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Trading Ideas

Here's How Much $100 Invested In Zoetis 10 Years Ago Would Be Worth Today

Wells Fargo analyst Stephen Baxter maintains UnitedHealth Group (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UNH#NYSE">UNH</a>) with a Overweight and lowers the price target from $677 to $351.

Wells Fargo Maintains Overweight on UnitedHealth Group, Lowers Price Target to $351

Commodities

Press Releases

Vista Publishes its 2023 Sustainability Report

Emvolon Reaches Commercial and Technical Milestones to Help Hard-to-Abate Industries Power the Global Economy While Eliminating Emissions

Vista Energy, S.A.B. de C.V. Files Form 20-F

Earnings

Vista announces the acquisition of Petronas Argentina

BMV:VISTA

MNTK

Antero Resources Corporation Common Stock

Antero Resources

Chord Energy

CNX Resources

ConocoPhillips

California Resources Corporation Common Stock

California Resources

Comstock Resources

Coterra Energy

Devon Energy

EOG Resources

Expand Energy

Diamondback Energy

Gulfport Energy Corporation Common Shares

Gulfport Energy

Hess

Magnolia Oil & Gas Corporation Class A Common Stock

Magnolia Oil & Gas

Matador Resources

Murphy Oil

Ovintiv

Permian Resources Corporation Class A Common Stock

Permian Resources

Range Resources

Texas Pacific Land Corporation Common Stock

Texas Pacific Land

Venture Global, Inc. Class A common stock

Venture Global

Viper Energy, Inc. - Class A Common Stock

Viper Energy

Woodside Energy Group Limited American Depositary Shares, each representing one Ordinary Share

Woodside Energy Group

Citigroup

JP Morgan

B of A Securities

Jefferies

지난주 가장 좋은 성과를 낸 중형주는 다음과 같다.
<ol>
<li>위불(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BULL#NASDAQ">BULL</a>) 주식은 <a href="https://www.benzinga.com//node/44876727" target="_blank" rel="noreferrer noopener">지난주 초 나스닥에 상장</a>되었고 주가는 119.05% 상승했다.</li>
<li>허츠 글로벌(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HTZ#NASDAQ">HTZ</a>) 주가는 99.03% 급등했다. 이는 빌 애크먼의 퍼싱 스퀘어 캐피털 매니지먼트가 수정된 13F를 제출하며 1,271만 주의 허츠 주식을 매수했다고 밝혔기 때문이다. 매입된 주식은 허츠 지분의 <a href="https://www.benzinga.com//node/44853443" target="_blank" rel="noreferrer noopener">약 4.1%을 의미한다.</a></li>
<li>멧세라(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTSR#NASDAQ">MTSR</a>) 주가는 49.62% 상승했다. 이는 화이자(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>)가 <a href="https://www.benzinga.com//node/44790653" target="_blank" rel="noreferrer noopener">다누글리프론(danuglipron) </a>개발을 중단했다는 소식에 따른 것이다.</li>
<li>비스타 에너지(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VIST#NYSE">VIST</a>) 주가는 35.52% 급등했다. 이는 회사가 9억 달러의 현금, 3억 달러의 후불, <a href="https://www.benzinga.com//node/44848713" target="_blank" rel="noopener">약 730만 ADS 단위</a>로 구성된 혼합 거래를 통해 페트로나스 E&amp;P 아르헨티나(Petronas E&amp;P Argentina)를 인수했다고 발표한 이후다.</li>
<li>시바니 스틸워터(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SBSW#NYSE">SBSW</a>) 주가는 27.76% 상승했다. 이는 아마도 금 가격이 3,300달러를 넘어 사상 최고치로 나아가는 랠리와 관련이 있다.</li>
<li>방코 마크로(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BMA#NYSE">BMA</a>) 주가는 27.71% 상승했다.</li>
</ol>
사진 제공: Shutterstock
Benzinga Pro의 독점 뉴스 및 도구로 수익률을 높이세요.
독점 속보 및 스캐너와 같은 Benzinga Pro의 강력한 도구 세트로 다른 트레이더보다 우위를 점하세요. <a href="https://www.benzinga.com/pro/register?t=be2bewe5mibe3bz3&amp;utm_source=bz-kor">여기를 클릭</a>하여 14일 무료 체험을 시작하세요.

Comments

Vista Energy

뉴스

에 대한 최신 뉴스 Vista Energy (NYSE:VIST) 주식

일요일, 4월 20, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌